Pallarès, Victor
Unzueta, Ugutz
Falgàs, Aïda
Sánchez-García, Laura
Serna, Naroa
Gallardo, Alberto
Morris, Gordon A.
Alba-Castellón, Lorena
Álamo, Patricia
Sierra, Jorge
Villaverde, Antonio
Vázquez, Esther
Casanova, Isolda
Mangues, Ramon
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00650, PIE15/00028, PI15/00378, EU COST Action CA 17140, FIS PI17/01246, RD16/0011/0028, FIS PI14/00450, FIS PI15/00272)
Agencia Estatal de Investigación (ES); Fondo Europeo de Desarrollo Regional (BIO2016-76063-R)
Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CB06/01/1031, 4NanoMets, VENOM4CANCER)
Agència de Gestió d’Ajuts Universitaris i de Recerca (2017 FI_B 00680, 2017-SGR-865, 2017-SGR-1395, 2017SGR-229)
Fundación Josep Carreras Contra la Leucemia (P/AG)
Fundación Cellex (Grant)
Departament de Salut, Generalitat de Catalunya (SLT002/16/00433, SLT006/17/00093)
Generalitat de Catalunya (CERCA Programme grant, ICREA ACADEMIA Award)
Fundación Española de Hematología y Hemoterapia (Grant)
Article History
Received: 4 November 2019
Accepted: 24 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: All procedures performed on animals were conducted in accordance with the guidelines approved by the institutional animal Ethics Committee of Hospital Sant Pau.
: Not applicable.
: EV, RM, and AV are co-founders of Nanoligent, a company devoted to develop anticancer drugs based on proteins.UU, EV, AV, RM, and IC are cited as inventors in a patent application (EP11382005.4) covering the therapeutic use of T22. All other authors report no conflicts of interest in this work.